PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases

被引：31

作者：

Wakade, Deepal V. ^{[1
,2
]}

Carlos, Giuliana ^{[1
,2
]}

Hwang, Shelley J. E. ^{[1
,2
]}

Chou, Shaun ^{[4
]}

Hui, Rina ^{[2
,3
]}

Fernandez-Penas, Pablo ^{[1
,2
]}

机构：

[1] Univ Sydney, Westmead Hosp, Dept Dermatol, Sydney, NSW 2006, Australia

[2] Univ Sydney, Sydney Med Sch Westmead, Sydney, NSW 2006, Australia

[3] Westmead Hosp, Dept Med Oncol, Sydney, NSW, Australia

[4] Westmead Hosp, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia

来源：

MELANOMA RESEARCH | 2016年 / 26卷 / 04期

关键词：

acitretin; bullous lichen planus; PD-1; MELANOMA; SAFETY;

D O I：

10.1097/CMR.0000000000000263

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The introduction of immunotherapy such as antiprogrammed death1 (anti-PD1) monoclonal antibodies has changed the scenario of treatment in cancer. Apart from their impressive efficacy profiles, they are better tolerated than the anticytotoxic T-lymphocyte-associated protein 4 antibodies. Dermatological adverse events such as pruritus and rash have been reported in various clinical trials. We report three cases of anti-PD1-induced bullous lichen planus (LP)-like reactions encountered in our institution. These patients developed LP-like papules and annular plaques with vesicles or crusted centres. Histology showed LP-like changes with negative immunofluorescence. Vesiculobullous lesions in patients treated with anti-PD1 therapies require a careful clinicopathological evaluation. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

引用

页码：421 / 424

页数：4

共 12 条

[1] PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
Blank, C
Brown, I
Peterson, AC
Spiotto, M
Iwai, Y
Honjo, T
Gajewski, TF
[J]. CANCER RESEARCH, 2004, 64 (03) : 1140 - 1145
[2] BULLOUS LICHEN PLANUS CAUSED BY LABETALOL
GANGE, RW
JONES, EW
[J]. BRITISH MEDICAL JOURNAL, 1978, 1 (6116) : 816 - 817
[3] BULLOUS LICHEN PLANUS AND LICHEN PLANUS PEMPHIGOIDES - CLINICOPATHOLOGICAL COMPARISONS
GAWKRODGER, DJ
STAVROPOULOS, PG
MCLAREN, KM
BUXTON, PK
[J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1989, 14 (02) : 150 - 153
[4] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Hamid, Omid
Robert, Caroline
Daud, Adil
Hodi, F. Stephen
Hwu, Wen-Jen
Kefford, Richard
Wolchok, Jedd D.
Hersey, Peter
Joseph, Richard W.
Weber, Jeffrey S.
Dronca, Roxana
Gangadhar, Tara C.
Patnaik, Amita
Zarour, Hassane
Joshua, Anthony M.
Gergich, Kevin
Elassaiss-Schaap, Jeroen
Algazi, Alain
Mateus, Christine
Boasberg, Peter
Tumeh, Paul C.
Chmielowski, Bartosz
Ebbinghaus, Scot W.
Li, Xiaoyun Nicole
Kang, S. Peter
Ribas, Antoni
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) : 134 - 144
[5] BULLOUS LICHEN-PLANUS
HANDA, S
KANWAR, AJ
[J]. PEDIATRIC DERMATOLOGY, 1993, 10 (04) : 393 - 394
[6] Familial bullous lichen planus (FBLP): Pedigree analysis and clinical characteristics
Huang, Changzheng
Chen, Siyuan
Lilt, Zhixiang
Tao, Yuan
Wang, Chunsen
Zhou, Youwen
[J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 (05) : 217 - 222
[7] Hwang SJ, 2016, J AM ACAD DERMATOL, V74
[8] Jaber SH, 2006, ARCH DERMATOL, V142, P166, DOI 10.1001/archderm.142.2.166
[9] Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study
Lage, Denise
Juliano, Priscila Bianchini
Metze, Konradin
de Souza, Elemir Macedo
Cintra, Maria Leticia
[J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2012, 51 (10) : 1199 - 1205
[10] PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Luke, Jason J.
Ott, Patrick A.
[J]. ONCOTARGET, 2015, 6 (06) : 3479 - 3492

← 1 2 →